Wyeth

Janssen Sciences Ireland Uc

University of Minnesota

Wyeth Holdings Corporation

Janssen Alzheimer Immunotherapy

Michael Hagen

A Krishna Prasad

Rasappa Gounder Arumugham

Annaliesa Sybil Anderson

Stephen Bruce Olmsted

Lakshmi Khandke

Susan Kay Hoiseth

Paul Patrick Cleary

Ingrid Lea Scully

Ingrid Lea Dodge

Yury Vladimirovich Matsuka

Thomas Newell Metcalf, Iii

P Patrick Cleary

Patrick P Cleary

Rasappa G Arumugham

The present invention is directed to methods of producing conjugates of A&#x3b2; peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.

A-&#x3b2; immunogenic peptide carrier conjugates and methods of producing same

A number of &#x3b2;-hemolytic streptococci polynucleotides and polypeptides, particularlypolypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by &#x3b2;-hemolytic streptococci.

Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease

A&#x3b2; immunogenic peptide carrier conjugates and methods of producing same

The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.

Adjuvant combination formulations

The present invention provides a method for producing a less-painful immunogenic composition of a hydrophobic protein in a pharmaceutically acceptable carrier suitable for administering to a mammal, comprising the steps of (a) solubilizing said hydrophobic protein with a zwitterionic detergent to make a first composition; (b) altering said first composition, such that the altered composition produces a reduction in pain as measured in the rat footpad model as compared to said first composition.

Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability

Growing community of inventors

Pittsford, NY, United States of America

Michael Hagen